Key Points
- Mirum Pharmaceuticals SVP Jolanda Howe sold 40,000 shares at $100 each, generating $4 million and reducing her direct ownership by 96.91% to 1,274 shares.
- Mirum reported quarterly revenue of $176.24 million, up 37.9% year over year and above estimates, but its adjusted loss of $1.06 per share missed consensus by $0.32.
- Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $137.33 versus the stock’s opening price of $102.24.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 40,000 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the sale, the senior vice president directly owned 1,274 shares of the company's stock, valued at $127,400. The trade was a 96.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jolanda Howe also recently made the following trade(s):
- On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $105.29, for a total value of $193,733.60.
- On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00.
- On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total value of $264,458.30.
Mirum Pharmaceuticals Trading Up 1.4%
Shares of MIRM stock opened at $102.24 on Thursday. The firm has a market cap of $6.64 billion, a P/E ratio of -7.03 and a beta of 0.52. The company has a 50 day moving average of $111.31 and a 200-day moving average of $102.02. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12-month low of $63.23 and a 12-month high of $130.00.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million during the quarter, compared to analysts' expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The firm's quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.12) earnings per share. Sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current year.
Institutional Trading of Mirum Pharmaceuticals
Hedge funds have recently modified their holdings of the stock. Contravisory Investment Management Inc. increased its holdings in Mirum Pharmaceuticals by 2.3% in the 2nd quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company's stock worth $539,000 after acquiring an additional 103 shares in the last quarter. ABS Investment Management LLC acquired a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth about $245,847,000. Faithward Advisors LLC raised its position in Mirum Pharmaceuticals by 0.5% in the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company's stock valued at $2,537,000 after purchasing an additional 126 shares during the period. Janney Montgomery Scott LLC lifted its stake in Mirum Pharmaceuticals by 6.7% during the 4th quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company's stock worth $253,000 after acquiring an additional 200 shares in the last quarter. Finally, Comerica Bank lifted its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company's stock worth $40,000 after purchasing an additional 278 shares in the last quarter.
Wall Street Analysts Forecast Growth
Several analysts have commented on the stock. Raymond James Financial restated a "strong-buy" rating and issued a $165.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Citigroup reaffirmed an "outperform" rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 6th. Stifel Nicolaus set a $136.00 target price on Mirum Pharmaceuticals in a report on Thursday, May 7th. JPMorgan Chase & Co. boosted their price objective on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an "overweight" rating in a research report on Thursday, July 2nd. Finally, Wolfe Research initiated coverage on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They issued an "outperform" rating and a $145.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $137.33.
Read Our Latest Report on Mirum Pharmaceuticals
Mirum Pharmaceuticals Company Profile
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
